SmithKline Coreg Sales are $44.3 Mil. After Six Months
Executive Summary
SmithKline Beecham's congestive heart failure therapy Coreg (carvedilol) will grow rapidly from its 1997 sales base of $44.3 mil., CEO Jan Leschly predicted at a Feb. 17 teleconference on SmithKline's sales and earnings for 1997.